Travere Therapeutics (TVTX) Receivables - Net: 2014-2025
Historic Receivables - Net for Travere Therapeutics (TVTX) over the last 12 years, with Sep 2025 value amounting to $83.0 million.
- Travere Therapeutics' Receivables - Net rose 229.37% to $83.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $83.0 million, marking a year-over-year increase of 229.37%. This contributed to the annual value of $27.1 million for FY2024, which is 28.03% up from last year.
- Travere Therapeutics' Receivables - Net amounted to $83.0 million in Q3 2025, which was up 114.37% from $38.7 million recorded in Q2 2025.
- Travere Therapeutics' Receivables - Net's 5-year high stood at $83.0 million during Q3 2025, with a 5-year trough of $11.9 million in Q2 2021.
- In the last 3 years, Travere Therapeutics' Receivables - Net had a median value of $24.5 million in 2024 and averaged $30.3 million.
- As far as peak fluctuations go, Travere Therapeutics' Receivables - Net dropped by 27.62% in 2021, and later skyrocketed by 229.37% in 2025.
- Travere Therapeutics' Receivables - Net (Quarterly) stood at $15.9 million in 2021, then grew by 4.60% to $16.6 million in 2022, then grew by 27.23% to $21.2 million in 2023, then increased by 28.03% to $27.1 million in 2024, then spiked by 229.37% to $83.0 million in 2025.
- Its last three reported values are $83.0 million in Q3 2025, $38.7 million for Q2 2025, and $34.4 million during Q1 2025.